NCT04831996View on ClinicalTrials.gov

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

July 8, 2022

Study Completion Date

July 8, 2022

Conditions
Advanced Malignancies
Interventions
DRUG

parsaclisib

parsaclisib will be administered orally after 8 hours of fasting.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Hialeah

55114

Prism Research, Saint Paul

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY